Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	109 people 3 RCTs in this analysis	Acute dystonia with haloperidol (4–75 mg/day) with placebo Absolute results not reported	RR 8.52 95% CI 1.66 to 43.85	Large effect size	placebo
Systematic review	333 people 4 RCTs in this analysis	Non-acute akathisia with haloperidol (0.75–20 mg/day) with placebo Absolute results not reported	RR 2.57 95% CI 1.39 to 4.75	Moderate effect size	placebo
Systematic review	246 people 3 RCTs in this analysis	Non-acute needing antiparkinsonian medication with haloperidol (6–75 mg/day) with placebo Absolute results not reported	RR 2.69 95% CI 1.53 to 4.72	Moderate effect size	placebo
Systematic review	163 people 4 RCTs in this analysis	Non-acute parkinsonism (including extrapyramidal symptoms) with haloperidol (1–75 mg/day) with placebo Absolute results not reported	RR 11.65 95% CI 2.88 to 47.11	Large effect size	placebo
Systematic review	99 people 3 RCTs in this analysis	Non-acute rigidity with haloperidol (0.75–75 mg/day) with placebo Absolute results not reported	RR 4.30 95% CI 0.94 to 19.74		Not significant
Systematic review	323 people 4 RCTs in this analysis	Non-acute tremor with haloperidol (0.75–200 mg/day) with placebo Absolute results not reported	RR 2.49 95% CI 0.59 to 10.49		Not significant
Systematic review	33 people Data from 1 RCT	Chronic dyskinesia and tardive dyskinesia with haloperidol (maximum dose 200 mg/day) with placebo Absolute results not reported	RR 2.83 95% CI 0.12 to 64.89		Not significant
Systematic review	364 people 3 RCTs in this analysis	Sleepiness with haloperidol (1–200 mg/day) with placebo Absolute results not reported	RR 3.43 95% CI 1.53 to 7.73	Moderate effect size	placebo
Systematic review	207 people Data from 1 RCT	Weight gain with haloperidol (10 mg/day) with placebo Absolute results not reported	RR 10.10 95% CI 1.32 to 77.46	Large effect size	placebo